AI Article Synopsis
- Tafamidis was approved for treating hereditary and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in May 2019, based on the ATTR-ACT clinical trial findings.
- A retrospective study analyzed the prescription patterns of tafamidis among 430 patients with ATTRwt-CM from May 2019 to December 2020, finding that 100% were prescribed within 9 months of diagnosis.
- Key factors influencing the prescription included being age 65 or older, male, having heart failure/cardiomyopathy, and undergoing specific heart imaging tests, indicating a need for further studies on real-world outcomes for these patients.
Article Abstract
Background: Tafamidis was approved for the treatment of hereditary and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in May 2019, based on findings from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).
Methods: This retrospective cohort study evaluated the factors associated with tafamidis prescription after diagnosis of ATTRwt-CM in the real world. Between May 2019 and December 2020, 430 patients with 6 months' database activity were indexed from the de-identified US Optum electronic healthcare records at first diagnosis of ATTRwt-CM or prescription of tafamidis, then followed until last activity or death. Of these, 209 patients were prescribed tafamidis during follow-up, 167 (80%) within 1 month, 98% by 6 months, and 100% by 9 months. Median time from index to tafamidis prescription, calculated using the Kaplan-Meier method, was 5.8 months (95% confidence interval [CI] 2.4-not evaluable).
Results: Factors associated with tafamidis prescription in a multivariable Cox proportional hazards regression (hazard ratio [95% CI]) included age ≥ 65 years (2.1 [1.07-4.05]), male sex (1.6 [1.07-2.28]), having heart failure/cardiomyopathy (2.4 [1.54-3.82]), and having had technetium-99m pyrophosphate myocardial scintigraphy (1.7 [1.28-2.28]).
Conclusions: The clinical characteristics of patients with ATTRwt-CM who were prescribed tafamidis in the real world were broadly comparable with those who took part in ATTR-ACT. Further studies are needed to evaluate hereditary and ATTRwt-CM patient populations in the real world and assess the long-term outcomes associated with disease management pathways.
Clinical Trials Registration: ClinicalTrials.gov identifier: NCT01994889.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006039 | PMC |
| http://dx.doi.org/10.1007/s40256-022-00563-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program.
Sci Rep
July 2024
Pfizer Inc, New York, NY, USA.
Tafamidis is the only disease-modifying therapy approved to treat patients in the United States with transthyretin amyloid cardiomyopathy (ATTR-CM), which most commonly affects patients aged ≥ 65 years. The manufacturer operates a patient assistance program (PAP) to support access to tafamidis. This study conducted Privacy Preserving Record Linking (PPRL) using Datavant tokens to match patients across Medicare prescription drug plan (PDP) and PAP databases to evaluate the impact of PAPs on treatment exposure classification, adherence, and persistence determined using Medicare PDP data alone.
View Article and Find Full Text PDFEffectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Eur J Neurol
September 2024
Neurology Department, Assistance Publique-Hopitaux de Paris (AP-HP), CERAMIC, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM U1195, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Article Synopsis
- Hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN) is a rare and progressing condition that causes various health issues, and this study looks at patients switching from tafamidis to patisiran treatment.
- The research involved reviewing medical records of 24 patients who switched treatments, focusing on demographic data, reasons for the switch, and health outcomes over time.
- Results showed that patients initially worsened on tafamidis but experienced slower disease progression and potential improvement after switching to patisiran, indicating the importance of timely treatment changes.
From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics.
Am J Health Syst Pharm
December 2024
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Article Synopsis
- AJHP is publishing peer-reviewed manuscripts promptly online before final formatting, indicating that these versions are not the final published articles.
- The study investigates the diagnosis and treatment pathway of transthyretin cardiac amyloidosis (ATTR-CA), highlighting a significant gap between estimated prevalence and actual treatment rates among at-risk patients.
- Results showed that 58.8% of diagnosed patients were prescribed tafamidis, with 80.7% of those starting treatment, while factors like younger age, gender, and race influenced prescription and treatment initiation rates.
Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.
ESC Heart Fail
October 2024
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Aims: This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (VYNDAQEL®) in Japan using the Japanese Medical Data Vision (MDV) database.
Methods And Results: This study was a non-interventional, retrospective cohort study of adult (≥18 years old) patients in the Japanese MDV claims database diagnosed with ATTR-CM and with at least two tafamidis prescriptions of dose strength 4 × 20 mg/day between 1 March 2019 and 31 August 2021. The date of the first prescription was defined as the index date, with follow-up time defined as the time between the first and last prescription plus the days' supply from the last refill.
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).
Cardiol Ther
June 2024
IQVIA, Frankfurt, Germany.
Article Synopsis
- - Tafamidis is the first drug approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, aiming to lower the risk of cardiovascular death and related hospitalizations, but its real-world usage in Germany is not well understood
- - A study analyzed data from 1,565 adults who filled a tafamidis prescription between March 2020 and August 2022, finding that the average age of participants was 78.3 years, with a majority being male and treated mostly by cardiologists
- - Results showed high adherence and persistency rates for tafamidis, with 78% of patients continuing treatment after 12 months and significant numbers consistently filling prescriptions, indicating the drug is generally well-t
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!